Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

Table 2 Sustained viral response 12 rate by various patient characteristics for non-cirrhotic patients with genotype 1 hepatitis C virus infection treated with 8-week ledipasvir/sofosbuvir therapy

Characteristics	SVR12 (%) (n = 736)	P value
Overall	96 (708/736)
Non-cirrhotic state determined by clinical judgement	96 (376/391)	0.962
Non-cirrhotic state determined by biopsy, VCTE, FIBROSPECT II	96 (332/345)
HCV RNA ≥ 2.2 million IU/mL	92 (201/219)	< 0.001
HCV RNA < 2.2 million IU/mL	98 (507/270)
HIV co-infection	100 (6/6)
HBV co-infection	100 (2/2)
Gender		0.071
Male	95 (383/403)
Female	98 (325/333)
HCV genotype-subtype		0.414
1a	96 (454/475)
1b	98 (236/324)
Undetermined	95 (18/19)
Ethnicity
Caucasian	96 (357/374)
African American	96 (171/178)
Hispanic	98 (155/158)	0.544
Asian/Pacific Islander	96 (25/26)
Age groups		0.311
< 55 yr	97 (216/223)
55-65 yr	97 (369/382)
> 65 yr	94 (123/131)
Fibrosis Tests		0.489
Liver biopsy	97 (306/317)
Vibration-controlled transient elastography	92 (23/25)
FIBROSPECT II	100 (3/3)
Overall fibrosis stage (cumulative: biopsy/VCTE/FIBROSPECT II)
Stage 0	98 (44/45)
Stage 1	95 (155/164)	0.611
Stage 2	98 (102/104)
Stage 3	97 (28/29)
Stage 4	100 (2/2)

HCV: Hepatitis C virus; VCTE: Vibration-controlled transient elastography; SVR: Sustained viral response.